Rhumbline Advisers grew its position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) by 11.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,234 shares of the biopharmaceutical company’s stock after purchasing an additional 2,608 shares during the period. Rhumbline Advisers owned about 0.08% of Loxo Oncology worth $2,325,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the business. Legal & General Group Plc increased its holdings in Loxo Oncology by 8.4% during the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 284 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Loxo Oncology by 31.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 419 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Loxo Oncology by 3.8% during the 2nd quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock worth $1,291,000 after acquiring an additional 592 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Loxo Oncology by 2.9% during the 3rd quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock worth $2,312,000 after acquiring an additional 700 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its position in shares of Loxo Oncology by 16.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 9,760 shares of the biopharmaceutical company’s stock worth $899,000 after purchasing an additional 1,400 shares in the last quarter. 99.98% of the stock is owned by hedge funds and other institutional investors.
Shares of Loxo Oncology, Inc. (NASDAQ LOXO) traded up $2.32 during trading hours on Tuesday, hitting $86.50. 376,245 shares of the company were exchanged, compared to its average volume of 438,788. Loxo Oncology, Inc. has a 1 year low of $30.51 and a 1 year high of $95.92. The company has a market cap of $2,590.00, a P/E ratio of -14.89 and a beta of 2.54.
In other news, insider Naarden Jacob Van sold 1,541 shares of the firm’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $86.52, for a total transaction of $133,327.32. Following the transaction, the insider now directly owns 1,541 shares of the company’s stock, valued at $133,327.32. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Avi Z. Naider sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $90.00, for a total transaction of $450,000.00. Following the transaction, the director now directly owns 144,118 shares in the company, valued at $12,970,620. The disclosure for this sale can be found here. In the last three months, insiders sold 1,614,555 shares of company stock valued at $124,567,942. 27.80% of the stock is owned by insiders.
LOXO has been the topic of a number of analyst reports. BidaskClub raised Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. William Blair assumed coverage on Loxo Oncology in a research report on Tuesday, November 28th. They issued an “outperform” rating on the stock. Zacks Investment Research cut Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Cowen reissued a “buy” rating on shares of Loxo Oncology in a report on Thursday, September 28th. Finally, Ifs Securities raised Loxo Oncology from an “outperform” rating to a “strong-buy” rating in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $90.57.
TRADEMARK VIOLATION NOTICE: “Rhumbline Advisers Boosts Position in Loxo Oncology, Inc. (NASDAQ:LOXO)” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.truebluetribune.com/2018/01/03/loxo-oncology-inc-loxo-stake-raised-by-rhumbline-advisers.html.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.